Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Systemic Lupus Erythematosus and Lupus Nephritis - Spain Drug Forecast and Market Analysis to 2022
Ist Teil von
M2 Presswire, 2013
Ort / Verlag
Coventry: Normans Media Ltd
Erscheinungsjahr
2013
Link zum Volltext
Beschreibungen/Notizen
Systemic lupus erythematosus (SLE) is a systemic inflammatory autoimmune disease that can affect any organ or tissue and is the prototypic autoimmune disease. While SLE can affect multiple major organ systems in the body, one of its most severe manifestations includes renal (kidney) involvement, known as lupus nephritis (LN). The term LN refers to SLE patients with glomerulonephritis, and when the term LN is used, glomerular tissue injury in the kidneys is always involved. Renal injury without any glomerular involvement is classified as nephritis in a patient with SLE. The SLE market in Spain will grow at a 14.78% CAGR by the end of the forecast period. Rituxan and MMF will remain the top-selling drugs in Spain, as lupus experts in Spain anticipate the percentage of patients using these products to increase.